Compare Adaptive Biotechnologies Corp (ADPT) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs J B Hunt Transport Services Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while J B Hunt Transport Services Inc trades at $273.8 (market cap $25.93B). The key difference: J B Hunt Transport Services Inc is far larger — about 7.8× Adaptive Biotechnologies Corp's market cap, and J B Hunt Transport Services Inc pays a 0.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JBHT | |
|---|---|---|
Market Cap | $3.33B | $25.93B |
Sector | Health | Industrials |
52-Week High | $22.37 | $290.07 |
52-Week Low | $10.24 | $130.65 |
Enterprise Value | $3.19B | $27.23B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JBHT trades at $275.00, down 3.79% over 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $12.00 billion in 2025 with a net income margin of 5.13%, and has beaten earnings estimates for the last three quarters. Recent news highlights its participation in industry conferences and positive analyst coverage amid a improving freight scenario.
The outlook for JBHT is supported by consistent earnings beats and a favorable analyst consensus, though high valuation ratios and exposure to freight market cyclicality present risks. Upside potential exists if the company maintains operational efficiency and capitalizes on industry tailwinds, but investors should weigh elevated P/E and P/B multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
